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http://dx.doi.org/10.1016/j.ccr.2012.11.006SUMMARYEpigenetic gene deregulation in cancer commonly occurs through chromatin repression and promoter
hypermethylation of tumor-associated genes. However, the mechanism underpinning epigenetic-based
gene activation in carcinogenesis is still poorly understood. Here, we identify a mechanism of domain
gene deregulation through coordinated long-range epigenetic activation (LREA) of regions that typically
span 1 Mb and harbor key oncogenes, microRNAs, and cancer biomarker genes. Gene promoters within
LREA domains are characterized by a gain of active chromatinmarks and a loss of repressivemarks. Notably,
although promoter hypomethylation is uncommon, we show that extensive DNA hypermethylation of CpG
islands or ‘‘CpG-island borders’’ is strongly related to cancer-specific gene activation or differential promoter
usage. These findings have wide ramifications for cancer diagnosis, progression, and epigenetic-based gene
therapies.INTRODUCTION
The individual epigenome of each cell type is formed during early
development and combines CpG DNA methylation and histone
modifications to orchestrate or mark tissue-specific gene
expression patterns. In normal cells, the bulk of the genome is
DNA methylated, but CpG-island-associated promoters of
active or bivalent genes commonly remain unmethylated (Cedar
and Bergman, 2009). The lack of methylation at CpG island
promoters is still an enigma, because although CpG dinucleo-
tides are the primary target for DNA methyltransferase enzymes
(DNAMTases), they remain essentially resilient to DNA de novo
methylation during normal development and differentiation.
Whether this is due to active or poised transcription and/orSignificance
Epigenetic changes, including alterations in histonemodificatio
associated with aberrant gene expression. However, most stu
thus, the mechanism that promotes gene activation in carcino
genomics approach in prostate cancer, we identify a mechanis
tion of multiple adjacent genes by remodeling of chromatin an
regions commonly contain key tumor genes, most notably the p
not previously been reported to be epigenetically regulated. Im
gene deregulation that promotes widespread oncogenic genebinding of the transcriptional machinery that obscures CpG sites
from DNAMTases, or to active demethylation remains to be
resolved (Clark andMelki, 2002). In cancer, however, CpG island
promoters are commonly hypermethylated, and this methylation
is associated with gene repression and gain of histone repres-
sive marks (Jones and Baylin, 2007). Our group and other inves-
tigators (Coolen et al., 2010; Frigola et al., 2006; Hsu et al., 2010)
have reported that epigenetic inactivation is not limited to single
genes but can also encompass large domains across the
genome during tumorigenesis, through long-range epigenetic
silencing (LRES). The characteristics of LRES are generally typi-
fied by concordant increases in CpG island hypermethylation
and gain or reinforcement of the repressive histone modifica-
tions H3K9 dimethylation (H3K9me2) and H3K27 trimethylationns and DNAmethylation, commonly occur in cancer and are
dies have focused on epigenetic gene-silencing events, and
genesis is still poorly appreciated. Here, using an integrated
m of regulation that involves coordinated epigenetic activa-
d DNA methylation patterns across domains. The activated
rostate cancer biomarker genes PSA and PCA3, which have
portantly, our study reveals a paradigm in epigenetic cancer
activation in tumorigenesis.
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Regional Activation of the Cancer Epigenome(H3K27me3), in conjunction with the loss of active H3K9
acetylation (H3K9ac) and H3K4 trimethylation (H3K4me3;
Coolen et al., 2010).
Studies examining the underlying mechanism of epigenetic
deregulation in cancer have primarily concentrated on DNA
hypermethylation and gene silencing, rather than DNA demethy-
lation and epigenetic gene activation. However, genome-wide
hypomethylation, initially reported by Feinberg et al. (1988), is
one of the primary epigenetic aberrations found in tumors.
Recently, it was reported that long-range hypomethylation
domains cover nearly half the cancer genome (Berman et al.,
2012) and commonly occur at partially methylated domains
(PMDs) in somatic cells (Hansen et al., 2011; Hon et al., 2012).
Traditionally, cancer-associated hypomethylation was attributed
to demethylation of the pervasive LINE-1 elements, as well as
other repeat sequences (Chalitchagorn et al., 2004; Ehrlich,
2002). More recently, demethylation of repeats was causally
implicated in the activation of alternative transcripts (Wolff
et al., 2010) and overexpression of oncogenes (Lamprecht
et al., 2010). CpG demethylation of gene promoters has also
been shown for several individual genes in cancer, including
R-RAS (Nishigaki et al., 2005) and cancer-testis antigens such
as the MAGE, GAGE, and XAGE families (Grunau et al., 2005;
Lim et al., 2005).
Even though epigenetic activation of specific genes has been
documented in cancer (reviewed in Ross et al., 2010), as yet no
genome-wide studies have specifically addressed the extent
and genomic context of epigenetic activation in cancer. Here,
we investigate the prevalence of regional activation in prostate
cancer and determine whether there are predominant chromatin
and DNA methylation changes associated with cancer-specific
gene activation covering large genomic domains.
RESULTS
Activated Domains Are Common in Prostate
Cancer Cells
To identify potential LREA regions in prostate cancer, we used
prostate cancer and normal prostate cell lines as well as publicly
available clinical expression data sets to categorize regions that
commonly display concordant cancer-associated gene activa-
tion. First, a list of transcriptionally upregulated regions was
created using Affymetrix Human Gene 1.0ST expression array
data, carried out in two normal primary prostate cells (PrECs)
and three prostate cancer cell lines (LNCaP, DU145, and PC3).
We preprocessed the data using robust multichip analysis
(RMA; Irizarry et al., 2003) and calculated themoderated t-statis-
tics (using limma; Smyth, 2004), representing the change in
expression in LNCaP over PrEC cells, for each represented
gene. The median t-statistic over a sliding window of five genes
was plotted for each chromosome as a representation of local
up- or downregulation (Figure S1A available online). Forty-two
activated domains were identified that had a median t-statistic
above 4. We found that 43% and 57% of the activated domains
identified in LNCaP cells were also consistently activated in PC3
and DU145 cells, respectively (Table 1). Figure 1A displays chro-
mosome 19, which shows two activated domains (regions 27
and 28), each of which harbors cancer-specific overexpression
of neighboring genes (Table 1). Notably, region 28 contains10 Cancer Cell 23, 9–22, January 14, 2013 ª2013 Elsevier Inc.a subset of the Kallikrein gene family (KLK15-KLK4), which
also includes KLK3, commonly known as prostate-specific
antigen (PSA; Figure 1B). Interestingly, region 28 is adjacent to
a region of transcriptional repression that also contains a subset
of the Kallikrein gene family (KLK5-KLK12). We validated the
gene expression array data using quantitative RT-PCR (qRT-
PCR) on genes from region 28 (Figures 1D and 1E) and regions
14, 23, and 25 (Figure S1B), and in all cases confirmed concor-
dant gene activation in cancer relative to normal cells.
Second, to exclude domains that showed a local increase in
expression due to potential copy number amplification, we
used genomic DNA inputs hybridized to Affymetrix Promoter
1.0R arrays to estimate promoter-level copy number changes
between the cancer cell lines and PrEC (see Supplemental
Experimental Procedures). Seven domains were excluded from
further analysis because they showed increased copy number
(p < 0.05) in LNCaP cells (Figure S1C), leaving 35 activated
regions. Unexpectedly, two domains showed a significant loss
of DNA copy number (4q31.1 and 14q11.1-q11.2) despite
concordant gene activation.
Third, to confirm the veracity and relevance of the activated
domains in clinical prostate cancer, we analyzed gene ex-
pression across clinical samples from nine large Oncomine pros-
tate cancer studies. This allowed us to compare expression in
215 normal prostate and 380 local prostate cancer samples, as
exemplified in Figure 1C for region 28 (19q13.33). The Oncomine
data from all activated domains are summarized in Figure S1D.
We found that 74% (26/35) of the activated domains identified
in LNCaP cells were also consistently activated in clinical pros-
tate cancer (Table 1).
Activated Domains Harbor Cancer-Related Genes
Using this rigorous approach, we identified 35 candidate LREA
regions harboring 251 genes that showed concordant transcrip-
tional activation (Table 1). The LREA regions span 32.5 Mb
(1% of the genome) and range in size from 85.5 kb to
5.2 Mb. Activated domains were identified on all chromosomes
except for 2, 17, 18, 21, and the Y chromosome (Figure S1A),
with chromosomes 7, 11, and 12 having the highest coverage
(3.3%, 3.9%, and 3.1%, respectively; Table 1). Each region con-
tained on average seven genes, with a mean 5.96-fold change in
expression in LNCaP compared with PrEC cells; indeed, 65.7%
of contained genes showed at least a 1.5-fold increase in gene
expression. Compared with normal genomic distribution, we
found no general significant increase in the density of genes or
CpG islands, or of SINE, LINE, Long Terminal Repeat, or simple
repeat density in activated regions (Figure S2).
Notably, 15% of the 35 activated domains we identified
contained gene clusters (Table 1). These included the MAGE
(Xq28: region 35) and GAGE cancer-testis antigens (Xp11.23:
region 32), UDP-glucuronosyltransferase type 2 family genes
(UGT2; 4q13.2: region 5), as well as genes from the Kallikrein
gene family (KLK; 19q13.33: region 28). We found that several
prostate-cancer-associated genes were also located within the
activated regions. In particular, two of the most sensitive pros-
tate cancer biomarkers, KLK3 (PSA; Lilja et al., 2008) and pros-
tate cancer antigen 3 (PCA3; Deras et al., 2008) were located
within regions 28 and 14, respectively. In addition, the LREA
regions harbored several genes, including C15orf21, KLK2,
Table 1. Summary of LREA Domains in Prostate Cancer
Identifier Band
Chromosome
Coordinates Size (kb)
No. of
Genesa
Average Fold
Change
% Up in
Oncomine
miRNA/
Oncogene Genes
1 * ^ 1q21.2 chr1: 149,035,
308 - 149,234,738
199.4 5 2.07 70 ARNT CTSK, ARNT, SETDB1, LASS2, ANXA9
2 * ^ 1q23.3 chr1: 159,357,
388 - 159,457,113
99.7 8 1.69 68.8 DEDD, UFC1, USP21, PPOX, B4GALT3, ADAMTS4,
NDUFS2, FCER1G
3 * ^ 3q13.2-q13.31 chr3: 114,948,
598 - 115,164,901
216.3 3 2.552 66.7 ATP6V1A, GRAMD1C, ZDHHC23
4 * ^ 3q13.33 chr3: 121,797,
818 - 122,748,178
950.4 6 16.96 70 NDUFB4, HGD, RABL3, GTF2E1, STXBP5L, POLQ
5 4q13.2 chr4: 68,995,
776 - 70,396,212
1,400.4 11 22.18 40 TMPRSS11E, UGT2B17, UGT2B15, TMPRSS11E, UGT2B15,
UGT2B10, UGT2A3, UGT2B11, UGT2B7, UGT2B28, UGT2B4
6 * 4q22.1 chr4: 89,398,
960 - 89,848,709
449.7 5 2.03 60 PPM1K, HERC6, HERC5, PIGY, HERC3
7 * 4q31.1 chr4: 140,594,
411 - 141,294,683
700.3 5 2.53 62.5 RAB33B, SETD7, MGST2, H3F3A, MAML3
8 ^ 5p13.2 chr5: 36,139,
171 - 36,724,193
585 5 4.71 50 mir-580 LMBRD2, SKP2, C5orf33, RANBP3L, SLC1A3
9 ^ 6q21 chr6: 110,608,
037 - 111,453,996
846 8 2.63 50 CDC40, C6orf186, DDO, SLC22A16, CDC2L6, AMD1,
GTF3C6, BXDC1
10 * ^ 7p12.2-p12.1 chr7: 49,947,
565 - 53,224,113
3,276.5 10 2.30 66.7 IKZF1 ZPBP, LOC100130988, LOC100130988, IKZF1, FIGNL1,
DDC, LOC100129427, GRB10, COBL, DKFZp564N2472
11 * ^ 7q21.13-q21.2 chr7: 89,621,
625 - 91,577,925
1,956.3 9 4.89 55.6 AKAP9 STEAP1, STEAP2, C7orf63, GTPBP10, CLDN12, PFTK1,
FZD1, MTERF, AKAP9
12 * ^ 8p21.2-p21.1 chr8: 27,224,
916 - 27,528,288
303.4 4 3.96 16.7 PTK2B, CHRNA2, EPHX2, CLU
13 * ^ 8q21.13 chr8: 80,685,
869 - 82,186,858
1501 5 2.41 80 STMN2, HEY1, MRPS28, TPD52, ZBTB10
14 9q21.13-q21.2 chr9: 78,190,
253 - 79,453,043
1,262.8 9 16.54 58.3 RFK, GCNT1, PCA3, PRUNE2, FOXB2, LOC645225,
VPS13A, LOC642947, GNA14
15 ^ 10q11.21 chr10: 43,201,
071 - 43,464,332
563.3 4 3.11 50 HNRNPF, ZNF239, ZNF485, ZNF32
16 * ^ 11p15.1-p14.3 chr11: 20,365,
679 - 25,566,989
5,201.3 10 2.6 55.6 FANCF PRMT3, SLC6A5, NELL1, ANO5, SLC17A6, FANCF,
GAS2, SVIP, LUZP2, LOC554234
17 * ^ 12p11.21 chr12: 31,118,
046 - 31,773,319
655.3 8 1.7 40 DDX11, OVOS2, FAM60A, FLJ13224, DENND5B, AK3L1,
C12orf72, AMN1
18 * ^ 12q14.2-q14.3 chr12: 63,084,
500 - 63,801,383
716.9 6 6.68 60 mir-548c XPOT, TBK1, RASSF3, GNS, TBC1D30, WIF1
19 * ^ 12q21.31 chr12: 80,177,
487 - 82,052,212
1,874.7 4 8.83 75 PPFIA2, CCDC59, C12orf26, TMTC2
20 * ^ 12q23.2 chr12: 100,073,
402 - 100,979,977
906.6 10 3.33 44.4 SLC5A8, UTP20, ARL1, SPIC, MYBPC1, CHPT1, SYCP3,
GNPTAB, DRAM, CCDC53
(Continued on next page)
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Table 1. Continued
Identifier Band
Chromosome
Coordinates Size (kb)
No. of
Genesa
Average Fold
Change
% Up in
Oncomine
miRNA/
Oncogene Genes
21 * 13q12.12 chr13: 22,653,
091 - 23,779,210
11,262.1 7 2.44 50 SGCG, SACS, TNFRSF19, MIPEP, PCOTH, FLJ46358,
SPATA13
22 * ^ 14q11.1-q11.2 chr14: 18,447,
594 - 19,251,915
804.3 6 3 0 OR11H1, A26C2, LOC440157, OR11H1, A26C2, OR11H1
23 * ^ 14q13.3-q21.1 chr14: 36,218,
829 - 37,752,019
1,533.2 6 9.14 70 SLC25A21, MIPOL1, FOXA1, C14orf25, TTC6, SSTR1
24 15q11.2 chr15: 22,705,
169 - 22,888,117
182.9 3 2.76 100 SNRPN, SNRPN, SNRPN
25 * ^ 15q21.1 chr15: 43,561,
968 - 43,689,685
127.7 3 8.85 66.7 C15orf21 SLC30A4, C15orf21, PLDN
26 16p12.2 chr16: 20,542,
060 - 20,768,491
226.4 5 5.07 90 ACSM1, THUMPD1, ACSM3, EXOD1, LOC81691
27 * ^ 19p13.2 chr19: 8,036,
287 - 8,293,278
257 5 2.29 50 FBN3, LASS4, CD320, NDUFA7, RPS28
28 * 19q13.33 chr19: 56,020,
357 - 56,105,806
85.5 5 10.21 100 KLK2 KLK15, KLK3, KLK2, KLKP1, KLK4
29 * ^ 20q11.21-q11.22 chr20: 31,334,
602 - 31,737,871
406.3 8 1.75 64.3 C20orf114, CDK5RAP1, SNTA1, CBFA2T2, NECAB3,
C20orf144, C20orf134, E2F1
30 * ^ 22q11.21 chr22: 16,973,
242 - 17,159,474
186.2 5 2.93 33.3 TUBA8, USP18, DKFZP434B061, LOC728212, GGT3P
31 * ^ 22q11.21 chr22: 18,681,
799 - 19,092,752
411 10 2.10 50 DGCR6L, LOC728212, DGCR6L, TMEM191B, PI4KAP2,
RIMBP3B, LOC728212, LOC728212, USP18, ZNF74
32 * Xp11.23 chrX: 48,978,
871 - 49,347,307
368.4 13 30.57 0 CCDC22, FOXP3, PPP1R3F, GAGE4, GAGE13, GAGE12C,
GAGE13, GAGE12C, GAGE12B, GAGE12B, GAGE12C,
GAGE12C, PAGE1
33 * ^ Xp22.22 chrX: 52,689,
836 - 54,488,645
1,798.8 20 1.73 46.4 mir-98/let-7f/
SSX2
SSX7, SSX2, SSX2, SPANXN5, XAGE5, XAGE3,
FAM156A, FAM156A, GPR173, TSPYL2, JARID1C,
IQSEC2, SMC1A, RIBC1, HSD17B10, HUWE1,
PHF8, FAM120C, WNK3, TSR2
34 * ^ Xq11.1 chrX: 62,435,
851 - 63,342,349
906.5 4 2.01 62.5 LOC645251, SPIN4, ARHGEF9, FAM123B
35 * ^ Xq28 chrX: 151,033,
182 - 151,688,896
655.7 12 10.37 28.6 mir-767/
mir-105
MAGEA5, MAGEA10, GABRA3, GABRQ, MAGEA6, CSAG2,
MAGEA2, MAGEA12, CSAG1, MAGEA2, CSAG2, MAGEA3
Average 926.81 7.06 5.96 55.77
See also Figure S2 and Table S1.
aNumber of genes in LREA regions in LNCaP cells.
*and ^symbols indicate regions that also contain genes upregulated in PC3 or DU145 cells, respectively, compared with PrEC cells. Underlined genes indicate those within gene families, and bold
indicates genes that contain CpG-island-associated promoters. Tumor genes denoted by the Wellcome Trust Sanger Institute Cancer Genome Project (http://www.sanger.ac.uk/genetics/CGP/
Census).
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Figure 1. Example of Gene-Activated
Domains in Prostate Cancer Cells
(A) The median t-statistic, representing change in
expression from LNCaP to PrEC over five genes, is
plotted for every locus on chromosome 19.
Designated regions 27 (R27) and 28 (R28) are
highlighted. The dotted line marks a median t-
statistic of 4, above which activated regions were
identified.
(B) Region 28 is magnified; red bars represent
the calculated t-statistic for each gene labeled on
the x axis. The line shows the median t-statistic
over five genes. The length of the x axis represents
chromosomal coordinates chr19:55,965,000–56,
231,000 (GPR32-KLK12).
(C) Summarized data extracted from nine Onco-
mine prostate cancer studies are plotted, aligned
to genomic coordinates spanning region 28. Red,
green, and gray boxes represent probe sets with
increased, decreased, and unchanged (or below
detection) expression, respectively.
(D) Expression data derived from Affymetrix
expression arrays for genes in region 28. The gray
box indicates values for which expression is
considered background.
(E) Validation of gene expression in region 28 by
qRT-PCR. Data are normalized to expression of
18S; error bars indicate ±SD.
See also Figure S1.
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Regional Activation of the Cancer Epigenomeand MIPOL1, that are implicated in translocations and gene
fusions with Ets-transcription factors in prostate cancer (Her-
mans et al., 2008; Tomlins et al., 2007). We confirmed that trans-
location of the Ets-transcription factor ETV1 gene into an intron
of MIPOL1 (14q13.3-q21.1: region 23) occurred in LNCaP cells
(Figure S2), as previously reported (Tomlins et al., 2007). Other
tumor-associated genes were also located in the activated
domains, including IKZF1 (7p12.2-p12.1: region 10; Mullighan
et al., 2009), FANCF (11p15.1-p14.3: region 16; Lim et al.,
2008), ARNT (1q21.2: region 1; Salomon-Nguyen et al., 2000),
AKAP9 (7q21.13-q21.2: region 11; Ciampi et al., 2005), andCancer Cell 23, 9–2SSX2 (Xp22.22: region 33; de Leeuw
et al., 1995; Table 1). Functional annota-
tion clustering using DAVID analysis
showed significant enrichment in several
gene families, including the MAGE and
UGT2 families (Table S1).
Epigenome Analysis of LREA
Regions
Next, we assessed whether these 35 acti-
vated regions also exhibited significant
epigenomic changes. We investigated
the relative enrichment of the active chro-
matin marks (H3K9ac and H3K4me3)
and repressive marks (H3K27me3 and
H3K9me2) in PrEC and LNCaP cells
across the domains using Affymetrix
Human Promoter 1.0R arrays (chromatin
immunoprecipitation [ChIP] on chip).
We analyzed DNA methylation usingamethod that incorporates methyl-CpG binding domain capture
with deep sequencing (MBDCap-seq; Robinson et al., 2010).
Summaries of tiling array signals for the 85 kb Kallikrein region
(19q13.33: region 28), where we observed a broad reorganiza-
tion of the epigenetic landscape, are shown in Figure 2. All of
the genes gained the active H3K9ac mark at their promoters
while they simultaneously lost the H3K27me3 repressive Poly-
comb mark. Changes in H3K9me2 and H3K4me3 were more
discrete, with losses of H3K9me2 at the promoter of KLK2,
and gains of H3K4me3 at the promoter of KLK4. There was
minimal change of DNA methylation in regions of low CpG2, January 14, 2013 ª2013 Elsevier Inc. 13
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Figure 2. Epigenome Plots across an Example Activated LREA
Domain
Histone modifications (H3K9ac, H3K4me3, H3K27me3, and H3K9me2) and
DNA methylation profiles (MBDCap-seq) are shown for each TSS from the
Kallikrein gene subfamily in region 28 (chromosome 19). For each gene and
each modification, the enrichment over input status is shown (green, PrEC;
red, LNCaP; black, differential LNCaP-PrEC). Locations of CpG islands in
region 28 are indicated. Black arrows mark the TSS for each gene. Note that
KLKP1 has no probes on the Affymetrix promoter array.
See also Figure S3.
Cancer Cell
Regional Activation of the Cancer Epigenomedensity (non-CpG islands) or in regions of high CpG density,
including CpG_28 (in the body of KLK15), which remained meth-
ylated and CpG_35 (4.6 kb upstream of KLK15), which remained
unmethylated. As discussed in more detail later, CpG_27 (in the
body of KLK4) was one of the few CpG islands found in LREA
regions to be hypomethylated in LNCaP cells (Figure 2).
Interestingly, we found that LREA region 28 is juxtaposed to
a neighboring LRES region containing Kallikrein genes (KLK5–
KLK12; Figure 1B). This region also undergoes epigenetic re-
modeling, but, in contrast to LREA region 28, gains repressive
epigenetic marks (LRES; Figure S3). The entire 92 kb region
gains the H3K27me3 repressive modification with localized14 Cancer Cell 23, 9–22, January 14, 2013 ª2013 Elsevier Inc.enrichment of H3K9me2. In addition, promoter-associated
CpG island hypermethylation (CpG_31, CpG_65, and CpG_69)
is associated with repression ofKLK8 andKLK10 in LNCaP cells.
We hypothesized that the boundary region spanning the LREA
and LRES might show differential CTCF binding in PrEC and
LNCaP cells. However, using CTCF-seq, we found that even
though there are two clear CTCF binding sites within the
LREA/LRES Kallikrein boundary region, there is little difference
in CTCF binding affinities between the normal and prostate
cancer cells (Figure S3). In addition, we found no clear differ-
ences in CTCF binding flanking the domain boundaries of the
other LREA regions (data not shown).
Activated Domains Are Epigenetically Deregulated in
Cancer Cells
Gene expression and histone modifications were analyzed
collectively for the 251 gene promoters in the 35 common
LREA regions in LNCaP cells. Overall, we found a significant
enrichment of the active H3K9acmodification at gene promoters
(±1,000 bp) from the transcription start site (TSS) and a general
depletion of H3K27me3 across the promoter region within the
activated domains compared with randomized gene sets (Fig-
ure S4). Although no such overall enrichment or depletion was
found for H3K4me3 or H3K9me2 modifications, changes in
these marks did occur in localized regions.
From a detailed epigenetic analysis, it is evident that LREA-
associated changes occur mainly in blocks of multiple consecu-
tive genes; however, various combinations of changes are
observed (Figures 3A–3E). For example, region 5 (4q13.2; UGT
gene family), region 23 (14q13.3; includes SLC25A21, MIPOL1,
FOXA1, C14orf24, TT6, and SSTR1), and region 28 (19q13.33;
Kallikrein gene family) all display a regional increase in H3K9ac
together with a regional loss of H3K27me3 (Figure 3A), whereas
region 4 (3q13.33), region 9 (6q21), and region 13 (8q21.13) all
show global increases in H3K9ac and H3K4me3 (Figure 3B). In
addition to those regions that exhibit combinations of epigenetic
alterations, many LREA regions show global changes predomi-
nantly in only one epigenetic mark. For example, regions 14
(9q21.13-q21.2) and 26 (16p12.2) are specifically depleted of
H3K27me3 (Figure 3C), regions 3 (3q13.2-q13.31) and 35
(Xq28) are depleted in H3K9me2 (Figure 3D), and regions 11
(7q21.13-q21.2) and 25 (15q21.1) show a predominant gain in
H3K9ac (Figure 3E).
Because tumor cell populations are thought to derive from
progenitor populations of stem-like cells (Lawson and Witte,
2007), we next askedwhether LREA regions also have a different
expression and chromatin profile in hES cells. We found signifi-
cant gene activation in LNCaP cells relative to gene expression
in human embryonic stem (hES) cells in the LREA genes, similar
to the differential expression observed in PrEC cells (Figure S6),
suggesting that this domain activation is a cancer-specific
phenomenon. Notably, when we compared the histone modifi-
cation profiles, we found that over half of the LREA genes were
bivalently marked in hES cells, that is, they harbored both
H3K4me3 and H3K27me3 marks (Figure S6). Interestingly,
gene activation in LNCaP cells for these genes was associated
with loss of the H3K27me3 mark but retention of the H3K4me3
modification at promoters. The significant enrichment of the
active H3K9ac modification observed in PrEC cells was less
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Figure 3. Epigenome Heat Maps of LREA Domains
Histone modification changes between LNCaP and PrEC cells are plotted across the TSS for each gene in an LREA domain, and various chromatin modes
are identified.
(A) Gain of H3K9ac and loss H3K27me3.
(B) Gain in both H3K9ac and H3K4me3.
(C–E) Concordant change in only one histone mark (H3K27me3, H3K9me2, or H3K9ac). Each row represents a single gene (named). Heat maps are divided into
four blocks showing changes in model-based analysis of tiling-array (MAT) scores at fixed intervals (2,500 to1,500,1,500 to500,500 to +500, and +500
to +1,500 bp) relative to the TSS (arrow), for each modification. Relative scale is shown in the bottom panel (green, loss; red, gain; black, not represented on the
array). Dotted boxes indicate regions with significant change between LNCaP and PrEC (p < 0.1).
See also Figure S4.
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Regional Activation of the Cancer Epigenomepronounced in comparison with hES cells, because many of
these genes were already bivalently marked.
Cancer-Associated DNA Methylation Changes
To determine whether DNA methylation changes were common
in promoter-associated CpG islands within LREA regions and
activated genes across the genome, we collectively compared
MBDCap-seq with changes in gene expression (Figure 4A).
The majority of CpG islands within 2.5 kb of a TSS were lowly
methylated in both PrEC and LNCaP cells, and therefore did
not show any significant change in methylation. Of the CpG
islands that did show a change in methylation, 2.5%were deme-
thylated, whereas 21% of CpG islands were hypermethylated in
LNCaP cells compared with PrECs (false discovery rate [FDR] <
0.05). A similar trend was also observed for CpG islands within
LREA regions, with 1% and 23% of promoter-associated CpG
islands losing or gaining methylation, respectively (FDR < 0.05;
Figure 4A). Moreover, 5% of all hypermethylated CpG islands
within 2.5 kb of a TSS were associated with transcripts that
gained expression (t-statistic > 4; Figure 4A, boxed area), and
15% were associated with gene repression (t-statistic < 4).As noted above, a CpG island (CpG_27) spanning the third
and fourth exons of the KLK4 gene was one of the few gene-
associated CpG islands that were demethylated in LNCaP cells
in association with gene activation (Figures 4A and 4B). How-
ever, the adjacent CpG island (CpG_22) 2 kb upstream of the
KLK4 TSS was conversely hypermethylated in LNCaP cells
(Figures 4A and 4B). When we examined this relationship further,
we noted that the majority of the KLK4 transcripts in LNCaP cells
originated from the second exon (Dong et al., 2005; Figure S5),
located 666 bp upstream of the hypomethylated CpG island
(CpG_27). The alternate ‘‘switching’’ of CpG island methylation
(CpG_27 and CpG_22) in the cancer cells is of particular interest
because these CpG islands flank the border between the two
alternately transcribed Kallikrein LREA and LRES regions (Fig-
ure S3). Because the epigenetic status of these CpG islands
could potentially regulate these domains, we investigated CpG
methylation and chromatin (H3K27me3 and H3K4me3) data
from H1 hES cells (Lister et al., 2009) to determine whether
they are differently marked in early development. Figure 4B
shows that for PrEC, CpG_22 is also unmethylated in hES cells
and is marked bivalently with H3K27me3 and H3K4me3. InCancer Cell 23, 9–22, January 14, 2013 ª2013 Elsevier Inc. 15
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Figure 4. Relationship between DNA Methylation and Gene Expression
(A) Expression change fromPrEC to LNCaP is plotted against changes in associatedCpG islandmethylation. All dots represent CpG islands foundwithin 2.5 kb of
a TSS; black dots indicate CpG islands found in LREA regions, and blue dots denote all genomic CpG islands. The x axis is the ±log10 of the FDR-adjusted p value
representing differences in MBDCap-seq counts obtained ±500 bp from the center of each CpG island (±log10 for islands that lose or gain methylation,
respectively). The y axis represents the t-statistic of change in expression between LNCaP and PrEC for genes associated with a given CpG island. The dashed
box indicates genes that significantly change in expression (t-statistic > 4) with a significant increase in promoter CpG island methylation (FDR-adjusted p
value < 0.05). The two KLK4-associated CpG islands are highlighted by black circles.
(B) KLK4 locus, indicating the relative location of the two associated CpG islands. The arrow above exon 2 indicates the TSS in LNCaP. Data fromMBDCap-seq
are plotted in blue for PrEC and red for LNCaP. DNA methylation, H3K27me3, and H3K4me3 data for the KLK4 locus from H1 ES cells (Lister et al., 2009) are
represented below.
(C) Bisulphite clonal sequencing, confirming differential methylation in two CpG islands in PrEC and LNCaP.
(D) Percentage ofmethylation from clonal sequencing (CpG sitesmethylated / total CpG sites3 100) of the twoKLK4CpG islands in PrEC, LNCaP, and six clinical
samples (three normal [N] and three tumor [T]). See Figure S5C for full clonal sequence data.
(E) qRT-PCR of KLK4 in PrEC and LNCaP (relative to the 18S); clinical samples (relative to the GAPDH). Error bars indicate ±SD.
See also Figure S5.
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methylated in hES cells.
We confirmed the switch in CpG methylation in cancer and
normal cells using bisulphite clonal sequencing and found that
CpG_27 was extensively methylated in PrEC, whereas only 1%
CpG sites were methylated in LNCaP (Figure 4C). Conversely,
CpG_22 was essentially unmethylated (2% of sites were methyl-
ated) in PrEC and extensively methylated in LNCaP cells. Pros-
tate tumors (n = 3) and normal prostate tissue (n = 3) isolated
from cancer patients were also investigated for changes inmeth-
ylation and expression associated with KLK4 (Figures 4D and
4E). Clonal sequencing showed that all normal samples were
extensively methylated at CpG_27 and were essentially unme-16 Cancer Cell 23, 9–22, January 14, 2013 ª2013 Elsevier Inc.thylated at CpG_22, whereas all tumor samples were hypome-
thylated at CpG_27 and hypermethylated at CpG_22 (Figure S5,
summarized in Figure 4D). This methylation switch corre-
sponded to KLK4 overexpression in these samples (Figure 4E).
Hypermethylation of Promoter-Associated CpG Islands
Associated with Gene Activation
The majority of the promoter-associated CpG islands that were
hypermethylated and showed transcriptional activation (as de-
picted in Figure 4A, boxed area) could be divided into two
main groups based on the cancer-specific methylation signature
and the TSS, as determined by RNA-seq and cap analysis gene
expression (CAGE)-seq (Figure 5). Group I (hypermethylation of
Cancer Cell
Regional Activation of the Cancer Epigenomepromoter-associated CpG island borders, but TSS remains un-
methylated and TSS is unaltered), includes PRUNE2 (CpG_75),
MMP16 (CpG_37), and IQGAP2 (CpG_126; Figure 5A). Group II
(extensive hypermethylation of CpG islands, including TSS, but
there is change in the TSS), includes TRIM36 (CpG_129),
ALOX15 (CpG_146), and MPP2 (CpG_63; Figure 5B). For each
activated transcript, we also found an increase in the H3K4me3
signal in the cancer cells at either the existing TSS for group I or
at the new TSS for group II genes (Figure 5). Interestingly, for
group I genes, we found that the cancer-specific hypermethyla-
tion across the CpG island borders was mutually exclusive to
the H3K4me3 signal. Genome-wide, we found that the group I
profile showing CpG island border methylation and gene activa-
tion was more common (88%) than the group II profile of hyper-
methylation and promoter switching (12%; Figure 5C). To deter-
minewhether hypermethylatedborders potentially promotegene
activation through binding inhibition of repressive factors, we
interrogated the hypermethylated loci of group I regions for
enrichment of transcription factor binding sites using the TRANS-
FAC database, and found significant enrichment of many tran-
scriptional repressor-associated DNA elements (Table S2).
Recently, focal hypermethylation was also reported to occur in
regions of long-range hypomethylation in colorectal cancer, and
these regions showed some enrichment of silenced genes within
LRES regions (Berman et al., 2012) and were associated with
cancer-gene-silencing programs (Berman et al., 2012; Hon
et al., 2012). However, we found no statistical enrichment (two-
tailed chi-square test, p > 0.05) of LREA regions in these
hypomethylated PMDs, supporting the conclusion that the
type I and II hypermethylated CpG islands are uniquely associ-
atedwith gene activation events independently of the long-range
hypomethylation observed in colorectal and breast cancers
(Berman et al., 2012; Hon et al., 2012).
We next asked whether these methylation changes were
cancer specific. By comparing Illumina 450K data, we found
that the changes in methylation observed in LNCaP cells at
promoter CpG islands are comparable if measured against the
PrEC or ES cell methylome (R2 = 0.804; Figure 5D). Notably,
both the group I and group II genes also showed a similar change
in methylation in LNCaP cells when compared with PrEC and ES
cells (R2 = 0.690), indicating that the gain of aberrant methylation
associated with activated transcription is cancer specific.
Epigenetic Changes Are Influenced by Changes
in Adjacent Genes
Finally, to ascertain whether epigenetic changes are influenced
by fluctuations in the local epigenomic environment, we quanti-
fied the incidence of epigenetic remodeling in adjacent genes in
LNCaP as compared with PrEC cells over the whole genome.
Figure S7 demonstrates how the frequency with which neigh-
boring genes exhibit the same epigenetic change over the TSS
compares with the ‘‘expected’’ random distribution. We found
that at each position relative to the TSS, all of the epigenetic
alterations (PrEC versus LNCaP) exhibited a significantly higher
frequency of neighboring modification than would be expected
by chance (p < 0.01). Increased H3K9ac and decreased
H3K27me3 at neighboring loci were strongly significant over
the entire promoter region (±1,000 bp from the TSS; p < 1 3
1010), while decreases in DNA methylation were found tohave the highest significance for enrichment of changes of any
epigenetic mark (p < 1 3 1043 over the whole promoter).
DISCUSSION
Transcriptional deregulation is common in cancer, and changes
involve both gene repression and gene activation. Given that one
of the main effectors of transcriptional deregulation is an alter-
ation in the epigenetic landscape, it is surprising that most
cancer genome-wide studies have focused on epigenetic
repression in preference to epigenetic-driven gene activation.
Primarily, this is due to the key role of DNA hypermethylation in
contributing to gene silencing, including silencing of tumor
suppressor genes, which is commonly promoted through dereg-
ulation of the Polycomb complex (Ohm et al., 2007; Schlesinger
et al., 2007). In contrast, gene activation studies in cancer have
mainly focused on promoter demethylation of individual genes
and global demethylation of repeat regions (Kalari and Pfeifer,
2010; Ross et al., 2010). However, global demethylation is gener-
ally thought to contribute to carcinogenesis by promoting
genome instability rather than oncogenic activation (Frigola
et al., 2006). We previously reported that regional epigenetic
repression, or LRES, commonly occurs in cancer and encom-
passes multiple genes that gain or exchange repressive histone
marks and are typified by DNA hypermethylation of neighboring
CpG islands (Coolen et al., 2010; Frigola et al., 2006). We now
show that similar epigenetic processes that shaped the cancer
epigenome into repressive domains can conversely create large,
multigene domains of epigenetic accessibility and consequential
transcriptional activation in cancer. The key findings of this study
can be summarized as follows:
First, by integrating gene expression, chromatin, and DNA
methylation genome-wide profiles in prostate cancer, we were
able to identify 35 LREA domains that harbor 251 genes,
including multiple gene families, and tumor-related genes. We
also found loci encoding microRNAs (miRNAs) within the LREA
regions, including let-7f, a member of the well-studied miRNA
let-7 family, which exhibits tumor suppressor and antigrowth
activity in prostate cancer (Liang et al., 2011), and miR-98, which
has been reported to potentially target EZH2 (Alajez et al., 2010).
In addition, two prominent prostate cancer biomarkers, KLK3
(PSA) and PCA3, were found embedded in LREA regions.
Although KLK3 can be expressed in normal prostate tissues, it
is highly overexpressed in cancer (Shaw and Diamandis, 2007).
PCA3 is a noncodingmessenger RNA that is extraordinarily pros-
tate cancer specific (de Kok et al., 2002). Little is known about the
transcriptional regulation of PCA3, but reports suggest that its
regulation is independent of the overlapping PRUNE2 gene
(Salagierski et al., 2009). Here, we show that the surrounding
PRUNE2 locus becomes depleted of the repressive H3K27me3
modification in cancer cells, indicating that epigenetic remodel-
ing may contribute to the biomarker’s prostate-cancer-specific
activation. Moreover, we noted that several genes and loci in
these remodeled LREA regions are commonly involved in
Ets-transcription-factor translocations (KLK2, C15orf21, and
MIPOL1) in prostate cancer (Kumar-Sinha et al., 2008), suggest-
ing that a more accessible chromatin structure may potentially
favor genetic instability and consequently prime these genes
for genomic rearrangement in prostate tumorigenesis.Cancer Cell 23, 9–22, January 14, 2013 ª2013 Elsevier Inc. 17
Figure 5. CpG Island Hypermethylation and Gene Activation
Two groups of CpG island methylation were found to be associated with activation of gene expression in LNCaP cells.
(A) Group I includes genes that showed a gain of DNA methylation at one or both of the flanking borders of a CpG island in association with gene activation.
(B) Group II genes showed extensive DNAmethylation spanning the entire CpG island, associated with a change in the TSS. Data fromMBDCap-seq are plotted
in blue (PrEC) and red (LNCaP). Data from H3K4me3 ChIP-seq are plotted in green (PrEC) and orange (LNCaP). RNA-seq and CAGE-seq profiles are plotted
below the RefSeq transcripts for each gene.
(legend continued on next page)
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Figure 6. Summary of Epigenetic Changes that Occurred in LREA Domains
In relation to regional gene activation in cancer cells, twomain modes of epigenetic change are found across promoter regions, in both histone modifications and
DNA methylation patterns.
(A) Exchange of histone marks: active H3K9ac is gained and repressive H3K27me3 mark is depleted.
(B) Gain of active marks: both H3K9ac and H3K4me3 levels are elevated.
(C) Gain of border CpG island methylation and H3K4me3, which we propose may prevent the binding of a repressor element, thereby activating ectopic
transcription.
(D) Extensive methylation at CpG islands results in a change of promoter usage and transcription from an alternative TSS.
See also Figure S7 and Table S2.
Cancer Cell
Regional Activation of the Cancer EpigenomeThe second key finding of the study is that the LREA domains
showed extensive changes in chromatin remodeling and could
be divided into two prominent modes of histone modification
alterations. Mode 1 (exchange of histone marks) is generally
characterized by an enrichment of the active histone modifica-
tion H3K9ac and depletion of the repressive histonemodification
H3K27me3 (Figure 6A). Mode 2 (gain of active histone marks) is
characterized by an enrichment of both H3K9ac and H3K4me3
(Figure 6B). Notably, over half of the LREA genes were bivalently
marked in hES cells, and gene activation in LNCaP cells was
associated with loss of the H3K27me3 mark but retention of
the H3K4me3 modification at promoters. These features are in
contrast to LRESdomains, which are notablymarked by a deple-
tion of the active epigenetic mark H3K9ac, an enrichment of
the repressive H3K27me3 modifications. In fact, the entire Kalli-
krein locus presents a remarkable example of the prominent
long-range switching that can occur in prostate cancer, where
the LREA domain that gains H3K9ac and loses H3K27me3modi-
fication is adjacent to an LRESdomain that gains H3K27me3 and
loses H3K9ac. It is interesting that the opposing transcriptional
domains are bordered by two CTCF sites. CTCF is reported to
be a boundary element/insulating protein that occurs at the
bases of known chromatin looping interactions (Tsai et al.,
2008), and is implicated in nuclear periphery positioning (Otta-
viani et al., 2009). Even though we found that CTCF binding at
the LREA/LRES boundary appears to be unaltered in the cancer
cells, other deregulated CTCF cofactors may be involved in(C) Summary of the percentages of group I and group II genes identified in LNC
characterization.
(D) Differences in methylation between LNCaP and H1 hES, and LNCaP and PrE
methylated regions (right). Group I and group II CpG islands are colored blue and
Infinium HumanMethylation450 BeadChip arrays (Statham et al., 2012), calculate
islands are represented as the average methylation over the specifically methyla
See also Figure S6.promoting switching between the two opposing epigenetic
domains.
The third key finding of this study is that CpG island DNA
hypermethylation is more commonly associated with gene
activation in prostate cancer than DNA promoter hypomethyla-
tion, primarily because the majority of CpG islands are already
unmethylated in normal prostate cells. However, we also found
isolated examples of CpG island DNA demethylation, specifi-
cally at the KLK4 locus, where concordant hypermethylation
of an upstream CpG island and demethylation of a downstream
CpG island within KLK4, resulted in transcriptional activation
from a new TSS at the second exon. Interestingly, we found
that the CpG island promoters associated with activated
transcripts were more commonly hypermethylated than hypo-
methylated, which is an intriguing contradiction. Evidence
suggests that methylated CpG sites can activate gene tran-
scription at low-CpG-density promoters (Rishi et al., 2010). In
this study, we show that DNA hypermethylation of CpG-rich
promoter regions is associated with cancer gene activation,
with two distinct profiles: group I methylation, where DNA
methylation encroaches the flanking regions of the CpG
islands, but specifically not the H3K4me3-marked TSS (Fig-
ure 6C); and group II methylation, which is characterized by
extensive methylation across the CpG island, including the
TSS (Figure 6D).
Group I hypermethylation is different from previously reported
cancer-specific methylation at CpG island shores, whichaP cells. Numbers in brackets indicate how many islands fall under a given
C, are plotted for all promoter-associated CpG islands (left) and group I and II
red, respectively. Each point represents the average beta value derived from
d ±500 bp from the center of each promoter-associated CpG island. Group I
ted region.
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more CpG-depleted regions (Irizarry et al., 2009) and is associ-
ated with gene repression in cancer and tissue-specific expres-
sion (Doi et al., 2009) or a change in promoter usage (Irizarry
et al., 2009). Hypermethylation has also been documented
at gene body CpG islands, resulting in the silencing of intragenic
transcription initiation sites (Maunakea et al., 2010). Gene
repression is also associated with focal CpG island hyper-
methylation located in regions of long-range hypomethylation
(Berman et al., 2012) or PMDs (Hon et al., 2012) and cancer-
specific DNA-methylated regions (Hansen et al., 2011). In
contrast, we found that group I hypermethylation at the borders
of CpG islands results in an augmentation of gene transcription
rather than gene repression. We propose that these flanking
regions could harbor repressive factor binding elements, and
that DNA hypermethylation relieves this repression through
binding inhibition, subsequently promoting gene activation (Fig-
ure 6C). In fact, a survey of the methylated CpG island flanking
sequences, using the TRANSFAC database, showed a highly
significant enrichment in transcription factor binding sites in
these regions (Table S2), many of which have repressor func-
tions. One of the most common transcription factor binding sites
found in the border regions was ZF5, which is a ubiquitous zinc
finger transcriptional repressor that also binds to two sites in the
c-myc promoter, modulating expression (Numoto et al., 1993).
However, future experiments are required to determine whether
the transcriptional repressors identified in this study are bona
fide targets of the border CpG island group I genes. In contrast
to group I genes, group II genes displayed extensive CpG island
hypermethylation across the TSS, and this resulted in ectopic
gene activation from alternative promoters in the cancer cell. In
all cases, this was also associated with a gain of H3K4me3
across the new promoter regions. Our results clearly demon-
strate that cancer-specific DNA hypermethylation of CpG
islands contributes to deregulation of promoter usage, and can
result not only in gene repression but, notably, also in cancer-
associated gene activation.
Finally, evidence suggesting regional genomic deregulation is
further reinforced by our pairwise analysis of chromatin change,
which showed that neighboring promoters undergo similar
epigenetic remodeling in cancer for all chromatin marks
studied, including DNA methylation (Figure S7). Importantly,
neighboring remodeling was found to be significant for both
enrichment and depletion of all of the studied epigenetic
modifications. The causes of this regional bidirectional epige-
netic remodeling are still unclear, but it is possible that factors
that typically organize the genome into epigenetically and
transcriptionally appropriate domains themselves become de-
regulated. Currently, several organizational processes have
been described that could be causally related in the establish-
ment of LREA and LRES in cancer. It will be of considerable
interest to investigate the role of the spatial organization of
the genome, such as radial positioning within the nucleus (Singh
Sandhu et al., 2011; Strasa´k et al., 2009), association with the
nuclear lamina (Berman et al., 2012), and chromatin looping
structures (Hsu et al., 2010), in the deregulation of long-range
epigenetic control in cancer, as these processes are all instru-
mental in establishing epigenetic domains in differentiation
and disease.20 Cancer Cell 23, 9–22, January 14, 2013 ª2013 Elsevier Inc.EXPERIMENTAL PROCEDURES
ChIP Assays
ChIP assays were carried out according to the manufacturer’s protocol
(Upstate Biotechnology) as previously described (Coolen et al., 2010). The
antibodies used were specific for acetylated-histone H3 (H3K9ac; catalog
no. 06-599, Millipore), dimethyl-histone H3 (H3K9me2; catalog no. ab1220,
Abcam), tri-methyl-histone H3 (H3K27me3; catalog no. 07-449, Millipore)
and tri-methyl-histone H3 (H3K4me3; catalog no. ab8580, Abcam). More
details regarding the protocol can be found in Supplemental Experimental
Procedures.
Methylation Profiling by MBDCap-seq
The MethylMiner Methylated DNA Enrichment Kit (Invitrogen) was used to
isolate methylated DNA from LNCaP and PrEC cell lines as previously
described (Nair et al., 2011). We used 10 ng of captured DNA for library prep-
aration, and Illumina GAII sequencing to generate a 36 bp read length. We
mapped the 36 bp reads to the hg18 reference genome using Bowtie (Lang-
mead et al., 2009), with up to three mismatches. More details regarding the
protocol can be found in Supplemental Experimental Procedures.
Chromatin Mark Heat Map Analysis
Using the blocksStats procedure in the Repitools software package (Coolen
et al., 2010), we summarized the enrichment in 1,000 bp blocks (2,500
to1,500,1,500 to500,500 to +500, and +500 to +1,500) for each epige-
netic mark surrounding each LREA-associated TSS. We tested changes in
epigenetic marks for individual regions using geneSetTest from the R limma
package (Smyth, 2004).
Identification of Regions Showing Long-Range Epigenetic
Activation
Array data for two replicates each of LNCaP and PrEC RNA were pre-
processed using RMA (Irizarry et al., 2003) as implemented in the R package
aroma.affymetrix (Bengtsson et al., 2008). Moderated t-statistics representing
differential expression between LNCaP and PrEC cells were calculated
using limma (Smyth, 2004) for each gene on the array. We identified domains
of LREA by first defining the core region as the region in which the median
t-statistic over five genes was >4 for two sequential genes. This core
was then extended bidirectionally to encompass flanking genes that
were also assigned positive t-statistics for change in expression. We used
a five-gene sliding window as an arbitrary definition because this size allows
the identification of sizable activated domains. A detailed protocol can be
found in the findClusters procedure in the Repitools R package (Statham
et al., 2010).
RNA-seq, CAGE-seq, and Chip-seq Mapping
For RNA-seq, 75 bp single-end reads were mapped to the human genome
(build hg18) using TopHat (Trapnell et al., 2010), with RefSeq used as a refer-
ence transcriptome. Putative transcripts were assembled using Cufflinks
(Langmead et al., 2009) with the default parameters. CAGE libraries were
made by DNAFORM (Japan), and sequencing was performed by GeneWorks
(Australia). We mapped 29 bp reads derived from CAGE tags to the human
genome (hg18) using bowtie (Langmead et al., 2009), allowing up to three
mismatches. Reads that mapped to multiple places with equal numbers of
mismatches were discarded. For Chip-seq, we mapped 50 bp reads derived
from H3K4me3 and CTCF ChIP to the human genome (hg18) using bowtie
(Langmead et al., 2009), allowing up to three mismatches. Nonunique reads
and reads that mapped more than once (i.e., identical start sites) to a single
genomic location were excluded.
Infinium HumanMethylation450 BeadChip Arrays
HumanMethylation450 BeadChip array data for PrEC and LNCaP cell lines
were adapted from Statham et al. (2012). Arrays were hybridized and data
were processed as previously described (Statham et al., 2012). For CpG
island analysis, beta values representing methylation at individual probes
were averaged ±500 bp from the center of all CpG islands located within
2.5 kb of a TSS.
Cancer Cell
Regional Activation of the Cancer EpigenomeTumor Samples
Fresh-frozen clinical tissue sampleswere obtainedwith informed consent from
St. Vincent’s Campus Prostate Cancer Group (i.e., from men with localized
prostate cancer treated by radical prostatectomy), with appropriate ethical
approval from St. Vincent’s Campus Research Ethics Committee (Approval
No. H00/088). RNA and DNA were extracted using the TRIzol reagent
(Invitrogen).
ACCESSION NUMBERS
All data sets have been deposited in NCBI’s Gene Expression Omnibus (GEO).
Raw and analyzed tiling and expression arrays for LNCaP and PrEC can be
found under GSE24546; CAGE-seq, RNA-seq, CTCF-seq, H3K4me3-seq,
and DU145 and PC3 expression array profiling data sets can be found under
GSE38685.
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Supplemental Information includes seven figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online at
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